Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. 2011

Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
INSERM ERI3 Cancers & Populations, University of Caen Basse-Normandie (UCBN), University Hospital (CHU de Caen), Caen, France. guittet-l@chu-caen.fr

BACKGROUND The superiority of several immunochemical fecal occult blood tests (I-FOBT) over guaiac-based tests in colorectal cancer screening is now established. The aim of this study was to compare the analytical performance of 3 quantitative I-FOBTs. METHODS Stool samples from 10 healthy volunteers, initially I-FOBT negative, supplemented with human blood, were used to compare reproducibility and stability of measurement at varying storage temperatures (4°C, 10°C, 20°C, and 30°C) and durations before test analysis (1 to 10 days) for 3 I-FOBTs (New Hemtube/Magstream HT, OC-Auto sampling bottle3/OC-Sensor DIANA, and FOB Gold/SENTiFOB). Concentrations ranging from 0 to 350 μg Hb/g of feces were evaluated. RESULTS The measurement reproducibility of OC-Sensor was superior to Magstream and far superior to FOB Gold. For all tests, variability was essentially related to sampling. Detected hemoglobin (Hb) levels were substantially lower for all tests at temperatures above 20°C. At 20°C, this loss in concentration was less important with OC-Sensor (significant 1.7% daily decrease vs. 7.4% for Magstream and 7.8% for FOB Gold). At 30°C, daily loss was 8.6% with OC-Sensor, whereas after 24 hours, only 30% of the original Hb was detected with FOB Gold, compared to 70% with Magstream. No Hb was detected on day 5 for the latter 2 tests. CONCLUSIONS About reproducibility and temperature stability, OC-Sensor performed better than Magstream and far better that FOB Gold. CONCLUSIONS Independently of the chosen test, the delay between sampling and test processing should be reduced, the maximal admissible delay depending on ambient temperature.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D009780 Occult Blood Chemical, spectroscopic, or microscopic detection of extremely small amounts of blood. Fecal Occult Blood Test,Blood, Occult
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013048 Specimen Handling Procedures for collecting, preserving, and transporting of specimens sufficiently stable to provide accurate and precise results suitable for clinical interpretation. Specimen Collection,Collection, Specimen,Collections, Specimen,Handling, Specimen,Handlings, Specimen,Specimen Collections,Specimen Handlings
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D055088 Early Detection of Cancer Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior. Cancer Screening,Cancer Screening Tests,Early Diagnosis of Cancer,Cancer Early Detection,Cancer Early Diagnosis,Cancer Screening Test,Screening Test, Cancer,Screening Tests, Cancer,Screening, Cancer,Test, Cancer Screening,Tests, Cancer Screening

Related Publications

Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
April 2004, The American journal of medicine,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
May 2013, Gastroenterology,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
July 2018, International journal of cancer,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
March 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
January 1996, The New England journal of medicine,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
April 1985, Journal of the Mississippi State Medical Association,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
July 2008, Gastroenterology,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
October 1996, Japanese journal of cancer research : Gann,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
May 1997, Archives of internal medicine,
Lydia Guittet, and Elodie Guillaume, and Romuald Levillain, and Philippe Beley, and Jean Tichet, and Olivier Lantieri, and Guy Launoy
November 2012, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!